

Press release

Synairgen plc
(‘Synairgen’ or the ‘Company’)

Notice of Annual Report and Accounts and Annual General Meeting

Southampton, UK – 18 October 2011: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence of the lungs, announces that the Company's Annual Report and Accounts for the year ended 30 June 2011 has been posted to shareholders. A copy of the report can be found on the Company's website: www.synairgen.com.

Synairgen's 2011 Annual General Meeting ('AGM') will be held at 12 noon on Thursday 10 November 2011 at the offices of Fasken Martineau LLP, 17 Hanover Square, London W1S 1HU. The Notice of the AGM is included in the Annual Report and Accounts.

-Ends-

For further information, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer
John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

FinnCap

Geoff Nash, Christophen Raggett (Corporate Finance)
Stephen Norcross, Simon Starr (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Threadneedle Communications

Graham Herring
Josh Royston

Tel: + 44 (0) 20 7653 9850